Kezar Life Sciences, Inc. (KZR) 追踪市盈率为负值 -1.0, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 追踪盈利收益率为 -103.84%.
本页证实的标准:
SharesGrow 综合评分： 32/100 其中 1/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -2,570.8 | 0.00 | -1,326.11 | 0.00 | - |
| 2017 | -2,713.6 | 468.09 | -899.73 | 0.00 | - |
| 2018 | -1,937.9 | -22.10 | 412.66 | 0.00 | - |
| 2019 | -218.1 | -6.19 | 98.05 | 0.00 | - |
| 2020 | -550.3 | 12.97 | 162.93 | 0.00 | - |
| 2021 | -1,614.7 | -170.45 | 448.07 | 0.00 | - |
| 2022 | -695.0 | 240.94 | 175.74 | 0.00 | - |
| 2023 | -67.4 | -1.75 | 36.63 | 981.55 | - |
| 2024 | -5.9 | 0.33 | 4.19 | 0.00 | - |
| 2025 | -0.8 | 0.00 | 0.66 | 0.00 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-0.69 | $0.00 | $-8.99M | - |
| 2017 | $-0.65 | $0.00 | $-8.52M | - |
| 2018 | $-1.22 | $0.00 | $-23.17M | - |
| 2019 | $-1.65 | $0.00 | $-31.53M | - |
| 2020 | $-0.89 | $0.00 | $-38.99M | - |
| 2021 | $-1.01 | $0.00 | $-53.28M | - |
| 2022 | $-0.97 | $0.00 | $-65.32M | - |
| 2023 | $-1.40 | $7M | $-101.87M | -1455.3% |
| 2024 | $-1.15 | $0.00 | $-83.74M | - |
| 2025 | $-7.66 | $0.00 | $-56.03M | - |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-4.74 | $-7.58 – $-1.91 | $0.00 | $0.00 – $0.00 | 2 |
| 2027 | $-4.59 | $-6.70 – $-2.46 | $21M | $21M – $21M | 3 |
| 2028 | $-4.70 | $-11.49 – $-0.11 | $31.5M | $31.5M – $31.5M | 4 |
| 2029 | $-4.09 | $-4.09 – $-4.09 | $19.97M | $19.97M – $19.97M | 2 |
| 2030 | $-6.10 | $-6.10 – $-6.10 | $20.73M | $20.73M – $20.73M | 2 |
